Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ACTI.ST
- Price
- 0.20
- Stock movement down
- -0.01 (-3.64%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 205.86M
- Ent value
- 213.16M
- Price/Sales
- -
- Price/Book
- 147.04
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -2.77%
- 1 year return
- -16.76%
- 3 year return
- -24.18%
- 5 year return
- -25.00%
- 10 year return
- -21.42%
Last updated: 2025-06-22
DIVIDENDS
ACTI.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 147.04 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.07B |
| EPS (TTM) | -0.12 |
| FCF per share (TTM) | -0.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -1.60M |
| Operating income (TTM) | -42.30M |
| Net income (TTM) | -41.60M |
| EPS (TTM) | -0.12 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.20M |
| Net receivables | 4.40M |
| Total current assets | 10.70M |
| Goodwill | 0.00 |
| Intangible assets | 200.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 14.90M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 11.50M |
| Total liabilities | 13.50M |
| Shareholder's equity | 1.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -39.60M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -39.60M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -2971.43% |
| Return on Assets | -279.19% |
| Return on Invested Capital | -2971.43% |
| Cash Return on Invested Capital | -2828.57% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.20 |
| Daily high | 0.21 |
| Daily low | 0.19 |
| Daily Volume | 11.5M |
| All-time high | 130.62 |
| 1y analyst estimate | 0.50 |
| Beta | 0.47 |
| EPS (TTM) | -0.12 |
| Dividend per share | - |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 21 Aug 2025 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -99.85% | -2.53% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -92.12% | -11.04% |
| Avg time to new high | 7124 days | 12 days |
| Max time to new high | 7123 days | 1805 days |
COMPANY DETAILS
Marketcap
205.86M
Marketcap category
Small-cap
Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Employees
6
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found